Iovance Biotherapeutics
IOVA
6.90
-0.41
-5.61%
Iovance Biotherapeutics
US · IOVA
#1864 by market cap
Listed 1970
6.90
-0.41
-5.61%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:59
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 33 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.9 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 62.91% -0.94pp
- Institutions
- 369 +33
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund36.67%
Hedge Fund11.91%
Individual/Insider6.42%
VC/PE Fund6.26%
Public Company4.18%
Private Company2.70%
Insurance Company0.81%
Government Pension Fund0.32%
Other30.69%
Top holders as of 2026-09-30
BlackRock
8.19% · 37.90M sh
MHR Fund Management LLC
6.26% · 28.97M sh
Wayne Rothbaum
6.07% · 28.07M sh
State Street Global Advisors
4.69% · 21.70M sh
Two Sigma Investments, LP
4.11% · 19.01M sh
Vanguard Capital Management, LLC
3.98% · 18.40M sh
Vanguard Portfolio Management, LLC
2.65% · 12.28M sh
Geode Capital Management, LLC
2.26% · 10.45M sh
Millennium Management LLC
1.84% · 8.53M sh
Dimensional Fund Advisors
1.35% · 6.24M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 30 buys · 20 sells
| Name | Role | Stake |
|---|---|---|
| Wayne Rothbaum | Independent Director | 6.07% |
| Frederick Vogt | Interim CEO, President, General Counsel, Corporate Secretary & Director | 0.13% |
| Raj Puri | Chief Regulatory Officer | 0.06% |
| Daniel Kirby | Chief Commercial Officer | 0.03% |
| Igor Bilinsky | Chief Operating Officer | 0.03% |
| Michael Weiser | Independent Director | 0.03% |
| Friedrich Graf Finckenstein | Former Chief Medical Officer | 0.03% |
| Matthew Rosinack | Former Senior VP of Finance, Interim Principal Financial Officer & Principal Accounting Officer | 0.02% |
| Iain Dukes | Independent Chairperson | 0.01% |
| Corleen Roche | Chief Financial Officer | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-10 | Frederick Vogt | Interim CEO, President, General Counsel, Corporate Secretary & Director | Derivative Exercise and Sale | -191,303 | $7.55–8.09 |
| 2026-11-10 | Frederick Vogt | Interim CEO, President, General Counsel, Corporate Secretary & Director | Derivative Exercise and Retained | +8,697 | $7.55 |
| 2026-11-09 | Daniel Kirby | Chief Commercial Officer | Derivative Exercise and Sale | -3,935 | $8.08 |
| 2026-11-09 | Daniel Kirby | Chief Commercial Officer | Derivative Exercise and Retained | +6,065 | -- |
| 2026-11-05 | Corleen Roche | Chief Financial Officer | Derivative Exercise and Sale | -5,311 | $8.04 |
| 2026-11-05 | Corleen Roche | Chief Financial Officer | Derivative Exercise and Retained | +7,189 | -- |
| 2026-09-29 | Noah Berkowitz | Chief Medical Officer | Other Derivative Acquisition | +135,000 | $14.82 |
| 2026-09-29 | Noah Berkowitz | Chief Medical Officer | Other Derivative Acquisition | +180,000 | -- |
| 2026-09-07 | Igor Bilinsky | Chief Operating Officer | Derivative Exercise and Sale | -3,976 | $8.70 |
| 2026-09-07 | Igor Bilinsky | Chief Operating Officer | Derivative Exercise and Retained | +3,837 | -- |
| 2026-09-07 | Frederick Vogt | Interim CEO, President, General Counsel, Corporate Secretary & Director | Derivative Exercise and Sale | -6,638 | $8.70 |
| 2026-09-07 | Frederick Vogt | Interim CEO, President, General Counsel, Corporate Secretary & Director | Derivative Exercise and Retained | +8,988 | -- |
| 2026-09-07 | Raj Puri | Chief Regulatory Officer | Derivative Exercise and Sale | -4,478 | $8.70 |
| 2026-09-07 | Raj Puri | Chief Regulatory Officer | Derivative Exercise and Retained | +5,288 | -- |
| 2026-08-31 | Igor Bilinsky | Chief Operating Officer | Derivative Exercise and Sale | -4,472 | $8.28 |
| 2026-08-31 | Igor Bilinsky | Chief Operating Officer | Derivative Exercise and Retained | +4,317 | -- |
| 2026-08-31 | Frederick Vogt | Interim CEO, President, General Counsel, Corporate Secretary & Director | Derivative Exercise and Sale | -17,702 | $8.28 |
| 2026-08-31 | Frederick Vogt | Interim CEO, President, General Counsel, Corporate Secretary & Director | Derivative Exercise and Retained | +23,967 | -- |
| 2026-08-31 | Raj Puri | Chief Regulatory Officer | Derivative Exercise and Sale | -2,508 | $8.28 |
| 2026-08-31 | Raj Puri | Chief Regulatory Officer | Derivative Exercise and Retained | +2,962 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:59:47 · For reference only, not investment advice and not tailored to your situation.
Iovance Biotherapeutics discussion 0 comments